Kaiane Ibarra

Regulatory risk stands among the most pivotal factors investors assess when directing capital toward biotechnology and pharmaceutical companies, as these sectors rely heavily on government bodies to oversee product authorization, labeling practices, manufacturing requirements, and post‑market monitoring, and any single regulatory ruling can shape whether a therapy becomes a major success, faces prolonged delays, or ultimately fails to reach patients.From an investor’s perspective, regulatory risk describes the likelihood that a product or company may encounter postponed approvals, limiting conditions, unforeseen compliance expenses, or even full rejection, and evaluating this risk calls for a blend of scientific understanding, regulatory expertise, and…

Corporate venture capital arms, often called CVCs, have long existed at the intersection of strategy and finance. In recent years, their investment theses have shifted in meaningful ways, shaped by market volatility, technological acceleration, and changing expectations from parent companies. What once focused primarily on strategic adjacency is evolving into a more disciplined, data-driven, and globally aware approach.Transforming Strategic Flexibility into Tangible ValueHistorically, many corporate venture arms invested to gain early exposure to emerging technologies, even when the financial case was uncertain. Today, boards and chief financial officers increasingly expect clear value creation, both strategic and financial.Key changes include:Dual mandate…

Regulatory risk stands among the most pivotal factors investors assess when directing capital toward biotechnology and pharmaceutical companies, as these sectors rely heavily on government bodies to oversee product authorization, labeling practices, manufacturing requirements, and post‑market monitoring, and any single regulatory ruling can shape whether a therapy becomes a major success, faces prolonged delays, or ultimately fails to reach patients.From an investor’s perspective, regulatory risk describes the likelihood that a product or company may encounter postponed approvals, limiting conditions, unforeseen compliance expenses, or even full rejection, and evaluating this risk calls for a blend of scientific understanding, regulatory expertise, and…